Cantor Fitzgerald reiterated an Overweight rating and $21.00 price target on Cytokinetics (NASDAQ: CYTK). 4Q16 fully diluted EPS was $0.16 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE